Austin Angelo

About the Author Austin Angelo


Analysts Offer Insights on Consumer Goods Companies: Stmicroelectronics NV (STM), Infineon Technologies AG (OtherIFNNF) and Compagnie Générale des Établissements Michelin (OtherMGDDF)

There’s a lot to be optimistic about in the Consumer Goods sector as 3 analysts just weighed in on Stmicroelectronics NV (STM), Infineon …

Analysts Offer Insights on Healthcare Companies: Clovis Oncology (CLVS), CytomX Therapeutics Inc (CTMX) and Aslan Pharmaceuticals Ltd (ASLN)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Clovis Oncology (CLVS), CytomX Therapeutics …

Milestone Pharmaceuticals Inc (MIST) Has a New Rating from Cowen & Co.

In a report released today, Ritu Baral from Cowen & Co. initiated coverage with a Buy rating on Milestone Pharmaceuticals Inc (MIST) and …

Parsons Corporation (PSN) Initiated with a Buy at Cowen & Co.

Parsons Corporation (PSN) received a Buy rating and a $35 price target from Cowen & Co. analyst Cai Rumohr today.

Barclays Thinks Chemours Company’s Stock is Going to Recover

Barclays analyst Duffy Fischer maintained a Buy rating on Chemours Company (CC) on May 31 and set a price target of $42. The …

Cowen & Co. Thinks Five Prime Therapeutics’ Stock is Going to Recover

In a report released yesterday, Chris Shibutani from Cowen & Co. maintained a Buy rating on Five Prime Therapeutics (FPRX).

Barclays Keeps a Hold Rating on Biohaven Pharmaceutical Holding Co Ltd (BHVN)

Barclays analyst Geoff Meacham maintained a Hold rating on Biohaven Pharmaceutical Holding Co Ltd (BHVN) yesterday and set a price target of $55. …

Barclays Reaffirms Their Sell Rating on Prothena Corp (PRTA)

Barclays analyst Geoff Meacham maintained a Sell rating on Prothena Corp (PRTA) on May 29 and set a price target of $9. The …

Cowen & Co. Thinks BeiGene Ltd’s Stock is Going to Recover

In a report released today, Yaron Werber from Cowen & Co. maintained a Buy rating on BeiGene Ltd (BGNE), with a price target …

Merrill Lynch Believes VMware (VMW) Won’t Stop Here

Merrill Lynch analyst Kash Rangan reiterated a Buy rating on VMware (VMW) today and set a price target of $225. The company’s shares …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts